Cargando…

Belatacept: the challenges with transformational drugs

Detalles Bibliográficos
Autor principal:	Vincenti, Flavio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422674/ https://www.ncbi.nlm.nih.gov/pubmed/28540252 http://dx.doi.org/10.21037/tau.2017.03.07

Ejemplares similares

Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski, David, et al.
Publicado: (2012)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

A case of belatacept-induced chilblain lupus
por: Kinariwalla, Neha, et al.
Publicado: (2022)

Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens
por: Ashokkumar, Chethan, et al.
Publicado: (2015)

Health Financing Consequences of Implementing Health Transformation Plan in Iran: Achievements and Challenges
por: Doshmangir, Leila, et al.
Publicado: (2019)

CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
por: Silva, Marcos V., et al.
Publicado: (2012)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

A Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation
por: Chhun, Stéphanie, et al.
Publicado: (2023)

The Potential of ChatGPT to Transform Healthcare and Address Ethical Challenges in Artificial Intelligence-Driven Medicine
por: Ray, Partha Pratim, et al.
Publicado: (2023)

Challenges of drug supply: How Afghanistan is struggling
por: Roien, Rohullah, et al.
Publicado: (2021)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Belatacept: Coronavirus disease 2019 (COVID-19): case report
Publicado: (2020)

Conversion to belatacept after lung transplantation: Report of 10 cases
por: Brugière, Olivier, et al.
Publicado: (2023)

A Case of Cycloserine-Induced Lichenoid Drug Eruption Supported by the Lymphocyte Transformation Test
por: Kim, Jakyoung, et al.
Publicado: (2017)

Factors Associated With Reduced Anti-SARS-CoV-2 Antibody Responses After mRNA Vaccination in Kidney Transplant Recipients on Belatacept
por: Morena, Leela, et al.
Publicado: (2022)

Stricturing Crohn’s disease-like colitis in a patient treated with belatacept
por: Bozon, Anne, et al.
Publicado: (2017)

Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
por: Grannas, Gerrit, et al.
Publicado: (2014)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Anti-COVID-19 drugs, COVID-19 and anesthetics - The challenge for anesthesiologists
por: Garg, Rakesh, et al.
Publicado: (2022)

Use of Belatacept as Alternative Immunosuppression in Three Renal Transplant Patients with De Novo Drug-Induced Thrombotic Microangiopathy
por: Cicora, Federico, et al.
Publicado: (2013)

Challenges of Estimates in Drug-Related Overdose Deaths in Iran: Evidence from the Literature
por: ROSTAMI, Mehran, et al.
Publicado: (2020)

Eccrine Porocarcinoma (Malignant Eccrine Poroma): A Series of Eight Challenging Cases
por: de Almeida Luz, Murilo, et al.
Publicado: (2010)

The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
por: Snanoudj, Renaud, et al.
Publicado: (2007)

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti, Giovanbattista, et al.
Publicado: (2012)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition
por: Heleniak, Zbigniew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5drm68asn6uu353gl254gm8k0q